Two AstraZeneca drugs get EU backing for treatment of some breast cancers
AstraZeneca said on Monday its cancer drugs Lynparza, developed with Merck & Co and Enhertu, developed with Japan’s Daiichi Sankyo, were recommended for the treatment of some high-risk breast cancers in the European Union.
RELATED STORIES
Article continues after this advertisement
FEATURED STORIES
Article continues after this advertisement
READ NEXT
EDITORS' PICK